Lilly's $2.75B bet on AI-discovered therapeutics
Eli Lilly's record partnership with Insilico Medicine is the largest AI drug-discovery deal in history. Why now, what it actually buys, and what the second-derivative effects are.
The headline is the cheque. The interesting part is what Lilly is paying for: not a molecule, not a target list, but access to a platform that has already collapsed parts of the discovery cycle from years to months. Rentosertib's pulmonary-fibrosis data is the proof point that made this defensible inside Lilly's board.
The big story — Lilly × Insilico
Eli Lilly committed $2.75 billion to Insilico Medicine in the largest AI drug-discovery deal on record. The structure (upfront, milestones, equity) signals that Lilly is buying platform access for the long arc, not a single asset. Insilico's rentosertib programme is the clinical validation that made the cheque writable.
On our radar
PandaClaw launches its agentic AI for med-chem workflows — first credible end-to-end agent product I've tried in this space. The FDA and EMA jointly publish AI principles for drug review (read it; the convergence is more aggressive than expected). Benchling's usage report quietly admits what every CIO already knew: data fragmentation is the real bottleneck.
Quick signals
FDA's internal Claude-powered assistant goes from pilot to production. Life-sciences AI funding posts its strongest quarter on record. DrugCLIP screening posts a step-function improvement on a benchmark that finally matters. Lilly extends its NVIDIA-built lab — capacity, not flagging interest, is the binding constraint.